Sign in
Taking peoplePhase 2/3

A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation

Key facts

Who runs it
Shanghai University of Traditional Chinese Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
60 people, planned
Started
10 Dec 2025
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo control group
  • Human-derived active intestinal bacterial liquid group
Record updated
15 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Clear or suspected infection + SOFA score ≥ 2 points, and PaO₂/FiO₂ ≤ 300 mmHg
  • Capable of taking in nutrients (able to eat independently or receive enteral nutrition)
  • Voluntarily participate in this trial and sign the informed consent form

Who cannot take part

  • Individuals with severe immune deficiencies, such as those with AIDS, leukemia, and those using immunosuppressive drugs
  • Those who cannot undergo nasal-intestinal catheterization or other transplantation methods
  • Indications for exclusion from FMT (Fecal Microbiota Transplantation) include massive gastrointestinal bleeding, intestinal obstruction, organic intestinal disorders, and severe damage to intestinal mucosa
  • Pregnant women and lactating women
  • Patients who cannot cooperate to complete the study; Other situations where the researchers determine that a patient is not suitable for participating in the clinical trial

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Acute respiratory distress syndrome or acute lung injury

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis is a systemic inflammatory response syndrome triggered by infection, and it is a common critical illness in clinical practice, often leading to multiple organ dysfunction. Among these, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the most severe complications. The mortality rate of sepsis-related lung injury is extremely high, reaching 30% - 50%. The existing treatment methods are unable to effectively reduce the high mortality rate of sepsis-related lung injury, and there are no specific treatment measures targeting lung injury itself. Dysbiosis of the intestinal flora plays an important role in the occurrence and development of sepsis-related lung injury. Fecal microbiota transplantation (FMT), as an effective means of regulating the intestinal flora, has shown certain therapeutic potential in some clinical studies. However, current research on FMT for treating sepsis-related lung injury is still in its infancy, and its mechanism is not yet fully clear. The clinical efficacy and safety also lack high-quality evidence support. Therefore, conducting this project's research will provide theoretical basis for targeted microecological treatment of sepsis-related lung injury; establishing a new strategy of combined microbiota transplantation technology for treating patients with sepsis ALI, and providing new ideas and methods for clinical treatment.

The 2 groups in the trial

  • Evaluation of the clinical efficacy and mechanism of action of fecal microbiota transplantation (FMTPlacebo, for comparison

    The participants in this study will be divided into Group A and Group B. The participants in Group A will receive basic treatment and a placebo (provided by Shanghai Baoteng Medical Laboratory, specification: 50 mL per bottle, serial number: 250713-DZ) for treatment.

    Treatment: Placebo control group

  • Human-derived active intestinal bacterial liquidTreatment being tested

    The participants in Group B will receive basic treatment and human-derived active intestinal flora liquid (provided by Shanghai Baoteng Medical Laboratory, specification: 50 mL per bottle, serial number: 250713-GT122) for treatment. Two groups were infused with the corresponding bacterial solution and the placebo bacterial solution through the nasal tube.

    Treatment: Human-derived active intestinal bacterial liquid group

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
Criteria questions
Built from NCT07342205, who can take part
Record updated
15 January 2026